Recent Updates
Recently added Catalysts

Metastatic Head and Neck Squamous Cell Carcinoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.5Buniverse median $1.20B
Allocated capital$772M$1.5B competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank166/299crowding rank 177

Metastatic Head and Neck Squamous Cell Carcinoma is uncontested. Bicara Therapeutics (BCAX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Ficerafusp alfa in phase 2.

There is no public comparable to price it against. BCAX spreads its $1.5B market cap across 2 indications, so $772M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$772M of allocated capital sits in Metastatic Head and Neck Squamous Cell Carcinoma, ranking it 166th of 299 indications by the money committed to it.

Companies developing drugs for Metastatic Head and Neck Squamous Cell Carcinoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
BCAXBicara TherapeuticsFicerafusp alfaPhase 21$1.5BNo2 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Metastatic Head and Neck Squamous Cell Carcinoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Metastatic Head and Neck Squamous Cell Carcinoma has one competitor and a median of $1.5B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Pancreatic Ductal Adenocarcinoma1 company · $768M · median $3.8BUncontestedAdvanced Gastroesophageal Adenocarcinoma1 company · $767M · median $3.8BUncontestedGlioma1 company · $792M · median $2.4BUncontestedAdvanced EGFR Mutant Non-Small Cell Lung Cancer1 company · $794M · median $794MUncontestedCancer Pain1 company · $798M · median $4.0BUncontestedNon-Muscle Invasive Bladder Cancer (NMIBC)1 company · $723M · median $8.7BUncontestedRefractory Non-Hodgkin's Lymphoma1 company · $723M · median $8.7BUncontestedHPV-Related Carcinoma1 company · $723M · median $8.7BUncontested

Metastatic Head and Neck Squamous Cell Carcinoma pipeline questions

Which biotech companies are developing drugs for Metastatic Head and Neck Squamous Cell Carcinoma?

Bicara Therapeutics (BCAX, Ficerafusp alfa, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Metastatic Head and Neck Squamous Cell Carcinoma.

How advanced is the Metastatic Head and Neck Squamous Cell Carcinoma pipeline?

Of the 1 clinical-stage programme in Metastatic Head and Neck Squamous Cell Carcinoma, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Metastatic Head and Neck Squamous Cell Carcinoma?

No. BCAX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Metastatic Head and Neck Squamous Cell Carcinoma, which is why the indication is classified as uncontested.

When is the next Metastatic Head and Neck Squamous Cell Carcinoma catalyst?

The next dated catalyst in Metastatic Head and Neck Squamous Cell Carcinoma is BCAX on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map